  | |||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
| Journal Home | |
| Current Issue | |
| AOP | |
| Archive | |
| |
| |
THIS ARTICLE  | |
| |
| Download PDF | |
| References | |
| |
| |
| |
| Export citation | |
| Export references | |
| |
| |
| |
| Send to a friend | |
| |
| |
| |
| More articles like this | |
| |
| |
| |
| Table of Contents | |
| | Next > | |
| |
 |
 |
| Nature 378, 532 (07 December 1995); doi:10.1038/378532c0 |
|
Anticancer drugs
David M. Reese
Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, California 90095, USA
| 1. | Petsko, G. A. Nature 377, 580−581 (1995). | Article | PubMed | ChemPort | |
| 2. | Takahara, P. M. et al. Nature 377, 649−652 (1995). | Article | PubMed | ISI | ChemPort | |
| 3. | Gottesman, M. M. & Pastan, I. Trends pharmac. Sci. 9, 54 (1988). | ChemPort | |
© 1995 Nature Publishing Group
Privacy Policy
